Form 4: Ginkgo Bioworks Director Canton Awarded 10 Million Stock Options with Performance-Based Vesting

Barry Canton, a director at Ginkgo Bioworks Holdings, was granted 10 million stock options with vesting tied to both time and the achievement of specific stock price targets.

Summary

• Barry Canton, a director of Ginkgo Bioworks Holdings, Inc., was granted 10,000,000 stock options on April 25, 2024.
• These options are divided into two tranches of 5,000,000 each, one held directly and one held indirectly by the spouse.
• The exercise price for the options is $2.50 per share.
• The options expire on April 25, 2034.
• The options are subject to both time-based and performance-based vesting criteria.
• The performance-based vesting is tied to achieving specific stock price hurdles within a five-year period.
• 10% of the options vest upon achieving a 90-day average stock price of $5.00.
• 10% of the options vest upon achieving a 90-day average stock price of $7.50.
• 20% of the options vest upon achieving a 90-day average stock price of $10.00.
• The remaining 60% of the options vest upon achieving a 90-day average stock price of $12.50.
• If the performance criteria are met, the awards will vest on the five-year anniversary of the grant date, contingent on continued employment.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future performance, but the vesting is contingent on achieving specific stock price targets.

Positives

• The performance-based vesting criteria align the director's interests with the company's stock performance.
• The long-term vesting schedule encourages continued commitment to the company's success.

Risks

• The performance-based vesting is contingent on achieving specific stock price targets, which may not be met within the five-year period.
• The vesting is also contingent on continued employment, so the options may be forfeited if the director leaves the company.

Future Outlook

The vesting of the options is dependent on the company's stock performance over the next five years, suggesting an expectation of growth and value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amyris and Zymergen (before its acquisition) also used stock options with performance-based vesting to incentivize executives.
• The specific stock price hurdles and vesting schedules vary depending on the company's stage of development and growth expectations.

Stakeholder Impact

• The stock option grant could incentivize the director to make decisions that increase shareholder value.
• The potential dilution of existing shares is a consideration for shareholders.

Key Dates